Lupin Limited reported a robust performance for the first quarter of FY27 (ended June 30, 2026). Total revenue surged by 33.3% year-on-year to ₹82,172 Mn. Profit After Tax (PAT) also saw a substantial increase of 16.0% to ₹14,170 Mn. The company highlighted strong growth across key markets, particularly in the U.S., India, and Emerging Markets.
Lupin Announces Strong Q1 FY27 Financials
Pharma major Lupin Limited has declared its unaudited financial results for the quarter ended June 30, 2026, showcasing significant year-over-year growth. The company’s total revenue reached ₹82,172 Mn, a notable increase of 33.3% compared to ₹61,638 Mn in the same quarter of the previous fiscal year (Q1 FY2026). This strong top-line performance was driven by broad-based growth across its operating segments.
Profitability and Key Financials
Profit After Tax (PAT) for Q1 FY2027 stood at ₹14,170 Mn, marking a 16.0% rise from ₹12,215 Mn in Q1 FY2026. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) grew by 42.8% to ₹25,799 Mn. The EBITDA margin improved to 31.4% from 29.3% in the prior year’s comparable quarter. Profit Before Tax (PBT) also saw a substantial jump of 42.5% to ₹20,174 Mn.
Sales Performance by Geography
The company detailed its sales mix, with the U.S. market contributing significantly, accounting for 42% of global sales with revenue of ₹34,348 Mn, up 42.9% year-on-year. India sales grew by 13.9% to ₹23,796 Mn (29% of global sales). Other Developed Markets saw a 48.3% increase to ₹11,494 Mn (14% of global sales), while Emerging Markets grew by 51.7% to ₹9,897 Mn (12% of global sales). Global API sales also increased by 8.5% to ₹2,637 Mn (3% of global sales).
Operational Highlights and Outlook
Lupin received 6 ANDA approvals from the U.S. FDA and launched 3 new products in the U.S. market during the quarter. Investment in Research and Development (R&D) for the quarter was ₹6,077 Mn (7.4% of sales). Mr. Nilesh Gupta, Managing Director, expressed optimism about the strong performance, emphasizing the focus on execution, operational excellence, and sustained investments in technology and innovation to drive profitable growth.
Source: BSE
